Study summary

One felzartamab course did not help people whose disease resisted rituximab

Felzartamab in rituximab-resistant disease · 10 people, single-arm study · Published June 2026, Kidney International Reports

What was tested

A 5-month course of felzartamab in adults with membranous nephropathy and nephrotic syndrome that had not responded to rituximab.

What they found

What it means

Suggests rituximab-resistant disease may need different or combined approaches.

Kidney Int Rep, via PubMed ↗ ← Back to the outlook
Last reviewed 2026-11-16 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.